<DOC>
	<DOCNO>NCT01800357</DOCNO>
	<brief_summary>This study seek evaluate efficacy safety mildronate injection treat acute ischemic stroke</brief_summary>
	<brief_title>Efficacy Safety Mildronate Acute Ischemic Stroke</brief_title>
	<detailed_description>randomize , double-blind , placebo-controlled phase II multicenter trial conduct evaluate efficacy safety mildronate injection patient acute ischemic stroke . patient randomized receive 14-day treatment placebo mildronate ( 500mg/5ml/each ) .Primary end-point modify Rankin scale 3 monthes . Secondary end-point NIHSS score Barthel index 8 day 15days . The safety end-point define incidence adverse event , change Samples routine laboratory test vital sign . Analysis intention treat .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>3- ( 2,2,2-trimethylhydrazine ) propionate</mesh_term>
	<criteria>clinical diagnosis acute ischemic stroke CT MRI brain image NIHSS scores:5~22 first stage intracranial pathology pregnant nursing significant drug alcohol misuse clinical trial past 3 month unlikely available followup give thrombolytic therapy medication forbidden study protocol neurological psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>randomize trial</keyword>
	<keyword>acute ischemic stroke</keyword>
	<keyword>mildronate</keyword>
</DOC>